Evidence map›Paper›PMID 27799900›Full record

ArticleFrontiers in behavioral neuroscience2016

VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome.

Laura Del Hoyo, Laura Xicota, Klaus Langohr, Gonzalo Sánchez-Benavides, Susana de Sola, Aida Cuenca-Royo, Joan Rodriguez, Jose Rodríguez-Morató, Magí Farré, Mara Dierssen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in behavioral neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Laura Del HoyoIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research InstituteBarcelona, Spain; Departament de Farmacologia, de Terapèutica i de Toxicologia, Universidad Autónoma de BarcelonaBarcelona, Spain.
Laura XicotaIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research InstituteBarcelona, Spain; Cellular & Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation, The Barcelona Institute of Science and TechnologyBarcelona, Spain; Department of Experimental and Health Sciences, Universidad Pompeu FabraBarcelona, Spain.
Klaus LangohrIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research InstituteBarcelona, Spain; Department of Statistics and Operations Research, Universidad Politècnica de Cataluña/BarcelonaTechBarcelona, Spain.
Gonzalo Sánchez-BenavidesIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain.
Susana de SolaIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research InstituteBarcelona, Spain; Cellular & Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation, The Barcelona Institute of Science and TechnologyBarcelona, Spain.
Aida Cuenca-RoyoIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain.
Joan RodriguezIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute Barcelona, Spain.
Jose Rodríguez-MoratóIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research InstituteBarcelona, Spain; Department of Experimental and Health Sciences, Universidad Pompeu FabraBarcelona, Spain; CIBER Fisiopatología Obesidad y Nutrición, Instituto Salud Carlos IIIMadrid, Spain.
Magí FarréIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research InstituteBarcelona, Spain; Departament de Farmacologia, de Terapèutica i de Toxicologia, Universidad Autónoma de BarcelonaBarcelona, Spain.
Mara DierssenCellular & Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation, The Barcelona Institute of Science and TechnologyBarcelona, Spain; Department of Experimental and Health Sciences, Universidad Pompeu FabraBarcelona, Spain; CIBER de Enfermedades Raras, Instituto Salud Carlos IIIMadrid, Spain.
Rafael de la TorreIntegrative Pharmacology and Systems Neuroscience Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research InstituteBarcelona, Spain; Department of Experimental and Health Sciences, Universidad Pompeu FabraBarcelona, Spain; CIBER Fisiopatología Obesidad y Nutrición, Instituto Salud Carlos IIIMadrid, Spain.
TESDAD Study Group
Municipal Institute for Medical Research · ESHospital Del Mar · ESHospital del Mar Research Institute · ESPompeu Fabra University · ESUniversitat Politècnica de Catalunya · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Down syndrome (DS) is an aneuploidy syndrome that is caused by trisomy for human chromosome 21 resulting in a characteristic cognitive and behavioral phenotype, which includes executive functioning and adaptive behavior difficulties possibly due to prefrontal cortex (PFC) deficits. DS also present a high risk for early onset of Alzheimer Disease-like dementia. The dopamine (DA) system plays a neuromodulatory role in the activity of the PFC. Several studies have implicated trait differences in DA signaling on executive functioning based on genetic polymorphisms in the genes encoding for the catechol-O-methyltransferase (

Indexed as

COMTVal158MetdopamineDown syndromePFC-dependent cognitionVNTR-DAT1

Identifiers

PMID27799900
PMCPMC5065956
OpenAlexW2531811227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.